STESTERIS plc (Ireland)

Ticker: STE | Price: $261.60 | Today's Change: +3.13%

---

What Happened

STERIS plc filed an 8-K with the SEC on November 12, 2026, disclosing its financial results for the second quarter of fiscal year 2027. The filing reports revenues of $2.851 billion, operating income of $511.8 million, and net income of $369.2 million for the quarter. The disclosure also includes full fiscal year 2026 earnings per share figures, with basic EPS of $3.83 and diluted EPS of $3.81, providing a comparative earnings baseline against the current reporting period.

---

Why It Matters

For investors, the Q2 FY2027 numbers represent a meaningful data point on STERIS's operational trajectory. Revenue above $2.85 billion in a single quarter signals sustained scale in the company's sterilization and healthcare services business. Operating income of $511.8 million translates to an operating margin of approximately 18%, indicating continued discipline in cost management even as the company operates across a broad, global footprint. The market's reaction — shares up more than 3% on the day of this report — suggests investors are reading these results favorably. This filing also coincides with StockWatch's initiating coverage of the company, published November 13, 2026.

---

Analysis

The Q2 FY2027 results reinforce STERIS's reputation as a steady, high-margin operator in the medical device and sterilization services space. A few key signals stand out:

• Revenue breadth: Quarterly revenue of $2.851 billion indicates the company is not reliant on a single segment or geography to drive top-line performance.
• Operating leverage: Operating income of $511.8 million against $2.851 billion in revenue reflects the kind of margin profile that tends to hold up well in periods of modest economic softening.
• Net income health: Net income of $369.2 million implies a net margin of roughly 13%, which is consistent with a business generating reliable free cash flow.
• FY2026 EPS as a baseline: The inclusion of FY2026 EPS data (basic: $3.83, diluted: $3.81) in the filing provides a year-over-year anchor point that analysts and investors will use to frame Q2 FY2027 performance within a longer earnings trajectory.

What to watch: Whether STERIS can sustain this revenue run rate through the back half of FY2027, particularly in its Applied Sterilization Technologies and Healthcare segments, will be the key question heading into the next earnings cycle.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in STERIS plc's SEC filing dated November 12, 2026, and publicly available market data. It does not constitute investment advice, and no Buy, Hold, or Sell rating is issued or implied herein. Investors should conduct their own due diligence before making any investment decisions.

Existing Coverage

StockWatch has full coverage on STE, published 2026-11-13. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-12. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1757898/000119312526458364/d195273d8k.htm